Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Adrenergic alpha 2A receptor (α2A adrenoceptor or ADRA2A) is a subtype of the alpha-2 adrenergic receptors, which are G protein-coupled receptors (GPCRs) involved in mediating physiological responses to catecholamines such as norepinephrine and epinephrine. It plays a key role in inhibiting neurotransmitter release, regulating vascular tone, and influencing cognitive functions. Agonists are used for hypertension, sedation, and ADHD treatment, while antagonists have been explored for reversing sedation and treating sexual dysfunction. Recent structural studies have provided insights into ligand binding and drug design.
Agonists activate the receptor, inhibiting adenylate cyclase and decreasing cAMP levels. Antagonists block the receptor, preventing activation by agonists.
29 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adrenergic alpha 2A receptor (α2A adrenoceptor).